Polpharma Biologics
Gdansk, Poland polpharmabiologics.com From their website, Nov 2026
- GMP
Work here? Claim this listing
About
Polpharma Biologics is a biosimilar developer and manufacturer based in Rotkreuz, Switzerland. It takes biosimilar programs from concept to commercial supply for partners in global, EU, US, and emerging markets.
Services
Biosimilar development & manufacturing
Develops biosimilars with analytical characterization, process development, formulation, and GMP manufacturing built for compliance and scale.
Cell line development
Provides cell line development as part of biosimilar development and manufacturing.
Process development
Develops efficient and scalable processes to support biosimilarity and commercial viability.
Formulation development
Supports formulation work for biosimilar programs.
Analytical characterization
Performs analytical characterization to establish biosimilarity.
Assays & in vitro testing
Clinical development
Provides clinical development in a lean and tailored approach, including strategy, execution, and reporting.
Clinical strategy and study planning
Plans clinical strategy and studies aligned with CMC and regulatory workstreams.
Regulatory strategy and dossier preparation
Builds unified regulatory strategies and dossiers for global submission.
10 more services
- Inspection readiness
- Tech transfer
- Device and delivery development
- Commercial supply
- Lifecycle management
- Quality
- IP and market landscape assessment
- GMP manufacturing
- Regulatory affairs
- Quality management
Capabilities
- Assays and studies
- Process development
- Analytical characterization
- Therapeutic areas
- Ophthalmology
- Neuroimmunology
- Gastroenterology
- Immunology
Modalities and species
- Modalities
- Biosimilar
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2013
- Office
- Erlenring 2, 6343 Rotkreuz, Switzerland
- Sites
- Rotkreuz, Switzerland
- Zug, Switzerland
- Serves
- Global, EU, US, Emerging markets